Key Points
- Stuart Rich bought a total of 5,000 shares of Tenax over Dec 2–4 (2,500 shares on Dec 4 at $9.20 plus 1,500 and 1,000 on prior days), spending about $45,630 in aggregate.
- Tenax is a small‑cap pharma (market cap ≈ $60.2M) trading near its 52‑week high, with negative earnings (last quarter EPS -$0.40) and a consensus analyst target of $18 (average rating: "Moderate Buy").
Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) insider Stuart Rich purchased 1,500 shares of the firm's stock in a transaction dated Wednesday, December 3rd. The shares were bought at an average cost of $9.08 per share, for a total transaction of $13,620.00. Following the completion of the purchase, the insider directly owned 2,766 shares of the company's stock, valued at $25,115.28. The trade was a 118.48% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Stuart Rich also recently made the following trade(s):
- On Thursday, December 4th, Stuart Rich acquired 2,500 shares of Tenax Therapeutics stock. The stock was bought at an average price of $9.20 per share, with a total value of $23,000.00.
- On Tuesday, December 2nd, Stuart Rich acquired 1,000 shares of Tenax Therapeutics stock. The stock was purchased at an average price of $9.01 per share, for a total transaction of $9,010.00.
Tenax Therapeutics Stock Up 3.2%
TENX stock opened at $9.65 on Friday. Tenax Therapeutics, Inc. has a twelve month low of $4.63 and a twelve month high of $9.91. The company has a market cap of $60.22 million, a P/E ratio of -8.54 and a beta of 1.55. The business has a fifty day moving average of $7.71 and a 200-day moving average of $6.61.
Tenax Therapeutics (NASDAQ:TENX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($1.33) by $0.93. As a group, equities research analysts anticipate that Tenax Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of Tenax Therapeutics in a research report on Monday. Guggenheim lowered their price objective on shares of Tenax Therapeutics from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Wall Street Zen raised Tenax Therapeutics to a "sell" rating in a research note on Saturday, October 25th. Finally, Piper Sandler started coverage on Tenax Therapeutics in a report on Monday, September 8th. They issued an "overweight" rating and a $20.00 price target for the company. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $18.00.
Read Our Latest Stock Report on TENX
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC increased its stake in Tenax Therapeutics by 98.1% in the 1st quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company's stock valued at $450,000 after buying an additional 34,048 shares during the last quarter. Virtu Financial LLC bought a new stake in Tenax Therapeutics during the third quarter worth about $92,000. Boothbay Fund Management LLC bought a new position in Tenax Therapeutics in the third quarter valued at approximately $2,680,000. Citadel Advisors LLC increased its position in shares of Tenax Therapeutics by 318.1% during the 3rd quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company's stock worth $329,000 after purchasing an additional 32,908 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Tenax Therapeutics by 34.2% during the 3rd quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company's stock worth $2,387,000 after buying an additional 79,998 shares during the last quarter. Institutional investors and hedge funds own 1.67% of the company's stock.
Tenax Therapeutics Company Profile
(
Get Free Report)
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
